The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials
The Indonesian Journal of General Medicine · 30.07.2026 · 43 (1) · 1-69
DOI: 10.70070/3gv2zv39 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Indonesian Journal of General Medicine, online erschienen am 30.07.2026. Verfasst von Muhamad Luthfi Asyhar und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Human epidermal growth factor receptor 2 (HER2) amplification characterises approximately 15–20% of invasive breast carcinomas and was historically associated with rapid visceral dissemination, central nervous system (CNS) tropism, and short survival. Over two decades, HER2-directed monoclonal antibodies, antibody–drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs) have progressively redefined the natural history of HER2-positive metastatic breast cancer (MBC). This systematic review was undertaken to synthesise, within a single comprehensive evidence framework, the magnitude, consistency, and safety trade-offs of HER2-targeted therapy across all treatment lines.
Methods
A systematic review of randomized controlled trials (RCTs) was conducted in accordance with PRISMA 2020. Eligible studies were phase II or III RCTs enrolling adults with HER2-positive advanced or MBC receiving at least one HER2-targeted agent. Two reviewers independently screened, extracted data, appraised risk of bias using Cochrane RoB 2, and rated certainty with GRADE. Effect estimates (hazard ratios [HRs] and risk ratios [RRs]) were pooled using DerSimonian–Laird random-effects inverse-variance models.
Results
Twenty-three RCTs comprising 9,808 randomized patients met eligibility. Across 18 trials, the pooled progression-free survival (PFS) HR for HER2-directed intensification versus control was 0.55 (95% CI 0.48–0.63; p
Zitieren
APA
Asyhar, M. L., Novianti, Y. A., Aziza, M. M., Cahyani, B. N., Situmorang, T. M., Faradila, Z., Rahmadina, R., & Sanjaya, C. (2026). The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials. The Indonesian Journal of General Medicine, 43(1), 1-69. https://doi.org/10.70070/3gv2zv39
Vancouver
Asyhar ML, Novianti YA, Aziza MM, Cahyani BN, Situmorang TM, Faradila Z, et al. The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials. The Indonesian Journal of General Medicine. 2026;43(1):1-69. doi:10.70070/3gv2zv39
BibTeX
@article{Asyhar2026,
author = {Asyhar, Muhamad Luthfi and Novianti, Yuke Aulia and Aziza, Mia Maya and Cahyani, Bernita Nur and Situmorang, Theresia Murniwati and Faradila, Zia and Rahmadina, Risa and Sanjaya, Charles},
title = {The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials},
journal = {The Indonesian Journal of General Medicine},
year = {2026},
volume = {43},
number = {1},
pages = {1--69},
doi = {10.70070/3gv2zv39}
}
EUVIMED